MoneyWorks4Me

Check Before You Invest : Kobo Biotech Ltd

BSE: 531541 NSE: ISIN: INE881A01015
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Kobo Biotech Ltd belong to?
Kobo Biotech Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Kobo Biotech Ltd a good quality company?
Kobo Biotech Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Kobo Biotech Ltd undervalued or overvalued?
Kobo Biotech Ltd appears Overvalued, as its key valuation ratios are higher than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios Current 0-year
Historic Median
Price to Earnings - 72.75
Price to Book -0.1 4.72
Price to Sales - 3.03
EV to EBITDA -128.52 40.82
Q.4 Is Kobo Biotech Ltd a good buy now?
Kobo Biotech Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

C: How much debt does the business have and is it at a sustainable level?

Q.1 Debt to Equity ratio of Kobo Biotech Ltd?
Kobo Biotech Ltd Debt-to-Equity ratio is -1.01, which is lower the industry average of , indicating lower debt levels in the industry.

Q.2 Debt to cash flow from operations of Kobo Biotech Ltd?
Kobo Biotech Ltd Debt to cash flow from operations is 33.46, which is at a unhealthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Kobo Biotech Ltd?

Q.1 Promoter shareholding and pledge status of Kobo Biotech Ltd?
Promoters hold 44.95% of the Kobo Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Kobo Biotech Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Kobo Biotech Ltd vs industry peers?
Kobo Biotech Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Profit Metrics
Current Level 0-year
Industry Median
Revenue Growth (%) - -
Gross Profit Growth (%) 0 20
Operating Profit Growth (%) 0 11.9
Net Profit Growth (%) 0 22
Operating Efficiency
Current Level 0-year
Industry Median
Asset Turnover (x) - 0.1
ROE (%) - 1.41
ROCE (%) - 3.87
Cash Conversion Cycle (days) - 438

Valuation & price assessment

Q.1 Stock return of Kobo Biotech Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -3.5% based on the current price.
9Y 5Y 3Y 1Y
Share Price
CAGR
-3.5% 2.4% 19.2% 111.8%
Q.2 Valuation ratios of Kobo Biotech Ltd vs historical?
The current P/E ratio of 0 is lower than its historical median of 72.75, indicating that the stock is trading below its historical average valuation.
Q.3 How do the current valuation ratios compare with 0-year historical median and industry numbers?
Valuation Ratios Current 0-year
Historic Median
0-year
Industry Median
Price to Earnings - 72.75 -
Price to Book -0.1 4.72 -
Price to Sales - 3.03 -
EV to EBITDA -128.52 40.82 -

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: